Global consulting · Buyer research

Public Research Institute

For public research institute teams, the immediate decision is to assess translational research programmes, technology options and public-interest dissemination. A structured evidence review can make that choice more transparent without implying a legal opinion or a guaranteed commercial outcome.

Technology & IP intelligenceSource-verifiable researchDefined outputs
Research and technology consulting for public research institute
Decision context

What public research institute leaders need to decide

Public institutions must compare technical readiness with mission value, public access and realistic private-sector uptake. A strong technical result may still require expensive validation before deployment.

Assess translational research programmes, technology options and public-interest dissemination. The research brief should identify the actual decision-maker, the point at which a choice becomes difficult to reverse, and the information that could change that choice. Describing an activity as urgent is not enough: the scope needs a decision and a dated review cycle.

In this setting, the crucial distinction is between collecting an impressive quantity of information and producing a reviewable account of what the information means. The output should record what is known, what remains uncertain and which next step will be authorized only after independent evaluation.

Evidence and provenance

Inputs that make the assessment credible

Use reproducibility evidence rather than promotional readiness labels. Separate scientific results, partner assertions and independent performance measurements. The proposed evidence intake below is illustrative; individual engagements require a scope agreed around confidentiality and lawful source access.

INPUT 01

Research outputs and maturity evidence

Record the source, date, permission to use the material, ownership of the claim and any contrary evidence. The associated decision question is: which results are replicable beyond the laboratory?

INPUT 02

Collaboration and funding conditions

Record the source, date, permission to use the material, ownership of the claim and any contrary evidence. The associated decision question is: which use cases align with the institute mission?

INPUT 03

Impact and market need documentation

Record the source, date, permission to use the material, ownership of the claim and any contrary evidence. The associated decision question is: how should public access and licensing options be compared?

Where an input is an interview statement, a vendor claim or an internal estimate, it should be labelled as such. A research team may compare sources and expose an inconsistency, but it should not quietly convert a claim into a verified fact. Each finding should therefore carry a traceable citation or an explicit uncertainty note.

Research workstreams

Three questions to answer before committing

QUESTION 01

Which results are replicable beyond the laboratory?

A focused research workstream examines research outputs and maturity evidence, searches for relevant comparator evidence, and tests whether translational research landscape is feasible. Findings are separated from assumptions and presented with a reviewer, date and suggested next action.

QUESTION 02

Which use cases align with the institute mission?

A focused research workstream examines collaboration and funding conditions, searches for relevant comparator evidence, and tests whether partner selection criteria is feasible. Findings are separated from assumptions and presented with a reviewer, date and suggested next action.

QUESTION 03

How should public access and licensing options be compared?

A focused research workstream examines impact and market need documentation, searches for relevant comparator evidence, and tests whether public-benefit evidence matrix is feasible. Findings are separated from assumptions and presented with a reviewer, date and suggested next action.

These workstreams are mutually informing but should not be conflated. An encouraging technical result may not resolve ownership; a documented ownership position may not demonstrate adoption; and a plausible commercial opportunity may still be subject to third-party permissions.

Decision-ready deliverables

Illustrative consulting work products

OUTPUT 01

Translational research landscape

This is an illustrative, version-controlled research output for the public research institute decision. It should identify the evidence reviewed, material gaps, alternative interpretations, accountable reviewers and the next meeting or approval at which it will be used.

OUTPUT 02

Partner selection criteria

This is an illustrative, version-controlled research output for the public research institute decision. It should identify the evidence reviewed, material gaps, alternative interpretations, accountable reviewers and the next meeting or approval at which it will be used.

OUTPUT 03

Public-benefit evidence matrix

This is an illustrative, version-controlled research output for the public research institute decision. It should identify the evidence reviewed, material gaps, alternative interpretations, accountable reviewers and the next meeting or approval at which it will be used.

Acceptance test

Decision test: stage gates specify technical performance, public benefit, partner contribution and a defensible stop rule.

Formats can include a dated memorandum, an evidence table, a workshop brief or a structured knowledge repository. The correct format depends on who will use it and how often the underlying evidence will change; it is not determined by document length alone.

Illustrative case

How the research might be used

A public institute is preparing an industry-partnership call for an emerging diagnostic platform. The research compares readiness and access models without claiming statutory approval

Hypothetical example only: no actual client, assignment result or measurable saving is represented here. A suitable engagement would first obtain authority to examine the relevant records, map conflicting stakeholder expectations and document what the evidence can establish without specialist determination.

Decision test: stage gates specify technical performance, public benefit, partner contribution and a defensible stop rule. If the evidence fails that test, the responsible team should either revise the research question, commission a defined further check, or decline to proceed. A negative finding can be a valuable result when it prevents an irreversible commitment.

Engagement method

Four-stage, reviewable research process

STEP 01

Define the decision

Agree who needs to decide, when, and how the public research institute case will be assessed. Exclude requests for advice outside the approved consulting scope.

STEP 02

Collect permitted evidence

Build a source register around research outputs and maturity evidence, collaboration and funding conditions and impact and market need documentation. Record document provenance and separate public records from controlled or confidential information.

STEP 03

Compare and challenge

Evaluate the three research questions against alternative hypotheses; state the strength of evidence, disagreements and checks needed before accepting a conclusion.

STEP 04

Deliver and transfer

Provide the agreed work products with a methods note, reviewer assumptions, update triggers and a short decision workshop. Identify which matters must go to qualified independent advisers.

Where the work spans several countries, the source register should identify the jurisdiction of each proposition and the date it was checked. Documents and analysis that have not been legally reviewed must not be presented as binding conclusions.

Professional scope

What the consulting output does not certify

Use reproducibility evidence rather than promotional readiness labels. Separate scientific results, partner assertions and independent performance measurements.

These pages describe technology research, IP intelligence, workflow design and commercial decision support. They are not offers to provide regulated legal representation across jurisdictions, securities recommendations, financial valuations, safety certification, medical opinions or governmental procurement determinations. Such work requires appropriate independent professionals and written engagement terms.

The enquiry process itself does not create a client relationship, guarantee confidentiality outside agreed arrangements, or authorize disclosure of third-party restricted documents. Submit only non-confidential context initially.

Buyer FAQs

Questions to resolve before engagement

Which results are replicable beyond the laboratory?

The review starts from research outputs and maturity evidence and evaluates whether translational research landscape would change the decision. Conflicting or incomplete evidence is recorded explicitly, and a responsible specialist reviews any regulated conclusion.

Which use cases align with the institute mission?

The review starts from collaboration and funding conditions and evaluates whether partner selection criteria would change the decision. Conflicting or incomplete evidence is recorded explicitly, and a responsible specialist reviews any regulated conclusion.

How should public access and licensing options be compared?

The review starts from impact and market need documentation and evaluates whether public-benefit evidence matrix would change the decision. Conflicting or incomplete evidence is recorded explicitly, and a responsible specialist reviews any regulated conclusion.

How would a public research institute start an enquiry?

Share the decision date, a short non-confidential description of the system or transaction and the intended research output. Sensitive documents should only be exchanged through an agreed confidential process.

Answers describe an illustrative research approach. Actual deliverables depend on reviewed source access, engagement terms and specialist requirements.

Project enquiry

Discuss a public research institute research question

Please share the decision, available source materials, countries or markets involved, the desired deliverable and the decision date. Do not attach confidential records before an appropriate intake is agreed.